Phase II Trial to Evaluate Trametinib in Patients With Advanced NF1-mutant Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Nov 2019 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2018 Status changed from not yet recruiting to recruiting.